ArticleACS pharmacology & translational science2025
Hydronidone Mitigates Pulmonary Fibrosis by Regulating the TGF-β/Smad2/3 Axis in
Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gymnemagenin-3-O-glucuronide mitigates lipopolysaccharide-induced acute lung inflammation/injury by regulating the NF-κB/MAPK signalling.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary fibrosis (PF) is a progressive, life-threatening lung disease marked by excessive accumulation of extracellular matrix (ECM), especially collagen, which leads to lung stiffening and impaired respiratory function. Although antifibrotic drugs like nintedanib and pirfenidone can slow disease progression, their clinical benefits remain modest. Hydronidone, a structural analogue of pirfenidone, has shown reduced/no hepatotoxicity, improved tolerability (in humans), and proven antifibrotic effects in liver fibrosis. This study investigated hydronidone's therapeutic potential in pulmonary fibrosis through both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.